MedTrace Logo

Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid

NCT01571895 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-12-22

No results posted yet for this study

Summary

The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development. The safety of DF2156A in the specific clinical setting was also evaluated.

Conditions

  • Bullous Pemphigoid

Interventions

DRUG

DF2156A

DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 \[CXCL8; formerly interleukin (IL)-8\] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.

Sponsors & Collaborators

  • Dompé Farmaceutici S.p.A

    lead INDUSTRY

Principal Investigators

  • Biagio Didona, MD · I Divisione di Dermatologia, Istituto Dermopatico dell'Immacolata, IRCCS; 00167 Roma, Italy

  • Detlef Zillikens, MD · Klinik für Dermatologie, Allergologie und Venerologie - Univ. Schleswig-Holstein; Lübeck, Germany

  • Andrea Kneisel, MD · Klinik für Dermatologie und Allergologie - Philips Universität; 35037 Marburg, Germany

  • Johannes Kern, MD · Department of Dermatology - Universitäts-Hautklinik; 79104 Freiburg, Germany

  • Pier Adelchi Ruffini, MD · Development Director Dompé s.p.a., 20122 Milan, Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-20
Primary Completion
2012-07-05
Completion
2012-07-05

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01571895 on ClinicalTrials.gov